clinical trial · NCT06133049
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
Bristol-Myers Squibb·—·active not recruiting·n = 2,961
Multiple SclerosisOzanimodSelect DMTs other than ozanimodNo DMTs
brief summary
The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with multiple sclerosis (MS) who were exposed to ozanimod during pregnancy; the second is women with MS exposed to select other disease-modifying therapies (DMTs) during pregnancy; the third is women with MS not exposed to any DMTs during pregnancy. This study will use data from a large US healthcare claims database.
started
Mar 16, 2021
primary completion
Mar 31, 2031
completion
Aug 31, 2031
last updated
Nov 15, 2023
official title
Zeposia (Ozanimod) Pregnancy Study: A Retrospective Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol